top of page

FDA Approves Higher Dosage of Naloxone

  • Ann Tucker
  • May 14, 2021
  • 1 min read

The Food and Drug Administration recently announced the approval of a higher dose of naloxone nasal spray to treat opioid overdose. The FDA previously approved 2 mg and 4 mg naloxone products and has now approved the delivery of 8 mg of naloxone. As described in the press release, the approval of 8 mg naloxone is another step the agency has taken to improve the availability of naloxone products. The agency has also encouraged manufacturers to pursue approval of over-the-counter naloxone products; required drug manufacturers for all opioid pain relievers and medicines to treat opioid use disorder (OUD) to add new recommendations about naloxone to prescribing information; and has extended the shelf life of naloxone from 24 months to 36 months. Read more

 
 
 

Recent Posts

See All

Comentarios


Subscribe to the CLASPP Newsletter

Our members and supporters stay informed. From state and federal policy news to training and webinar events, funding opportunities and more, CLASPP brings it to you first.

Thanks for submitting!

© 2022 by CLASPP

bottom of page